Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

FemaSeed^® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution

ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for U.S. Patent Application 18/443,798 further strengthening Femasys’ intellectual property position and coverage for the Company’s infertility therapeutic product FemaSeed^® Intratubal Insemination.

Read more at globenewswire.com